» Articles » PMID: 2785562

Tumor-specific Cytolysis by Lymphocytes Infiltrating Human Melanomas

Overview
Journal J Immunol
Date 1989 May 15
PMID 2785562
Citations 151
Authors
Affiliations
Soon will be listed here.
Abstract

Tumor infiltrating lymphocytes (TIL) were grown in IL-2 from single cell tumor suspensions of 14 human melanomas resected from 12 patients. As a function of time in culture, 4 of 14 TIL cultures eventually expressed highly specific cytolytic activity against fresh autologous melanoma targets in short term chromium release assays, failing to lyse multiple allogeneic tumors or autologous normal cells. These highly specific TIL were identified as CTL by phenotype (CD3+/CD4-/CD8+/Leu7-) and by function (lysis inhibited by antibodies directed against CD3 and MHC class I molecules). Cell separation experiments using immunomagnetic beads identified a highly tumor-specific CTL subpopulation within a nonspecific TIL culture, suggesting that the lytic activity of tumor-specific CTL may be diluted by the nonspecific killer activity present in heterogeneous TIL cultures. These studies provide evidence for specific MHC-restricted human immune responses against autologous tumor in cancer-bearing patients, and may be of importance to ongoing clinical trials using TIL in the immunotherapy of advanced malignancies.

Citing Articles

Therapeutic potential of tumor-infiltrating lymphocytes in non-small cell lung cancer.

Plaugher D, Childress A, Gosser C, Esoe D, Naughton K, Hao Z Cancer Lett. 2024; 605:217281.

PMID: 39369769 PMC: 11560632. DOI: 10.1016/j.canlet.2024.217281.


Defining melanoma combination therapies that provide senolytic sensitivity in human melanoma cells.

Tchelougou D, Malaquin N, B Cardin G, Desmul J, Turcotte S, Rodier F Front Cell Dev Biol. 2024; 12:1368711.

PMID: 38946802 PMC: 11211604. DOI: 10.3389/fcell.2024.1368711.


GTN Enhances Antitumor Effects of Doxorubicin in TNBC by Targeting the Immunosuppressive Activity of PMN-MDSC.

Mabrouk N, Racoeur C, Shan J, Massot A, Ghione S, Privat M Cancers (Basel). 2023; 15(12).

PMID: 37370739 PMC: 10296121. DOI: 10.3390/cancers15123129.


Antigen-specific and cross-reactive T cells in protection and disease.

Jiang N, Malone M, Chizari S Immunol Rev. 2023; 316(1):120-135.

PMID: 37209375 PMC: 10524458. DOI: 10.1111/imr.13217.


Mechanism of inert inflammation in an immune checkpoint blockade-resistant tumor subtype bearing transcription elongation defects.

Modur V, Muhammad B, Yang J, Zheng Y, Komurov K, Guo F Cell Rep. 2023; 42(4):112364.

PMID: 37043352 PMC: 10562518. DOI: 10.1016/j.celrep.2023.112364.